TriLink BioTechnologies
San Diego, CA
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
63.0
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (19)
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: TriLink BioTechnologies
- Signal Score
- 63.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- San Diego, CA
- Modalities
- mRNA, Oligonucleotide
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About TriLink BioTechnologies
Key mRNA raw material supplier. CleanCap technology.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA, Oligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: Maravai LifeSciences (MRVI)
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
19 SEC filings with industry mentions on record (shown, not scored)
SEC Filings19 with industry mentions (not scored)
Parent company: Maravai LifeSciences (MRVI)
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: San Diego, CA
Modalities: mRNA, Oligonucleotide
Capacity assessment: 58.0/100
Sites: San Diego, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals1 articles (not scored)
1 manufacturing site: San Diego, CA
Modalities: mRNA, Oligonucleotide
Capacity assessment: 58.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (3 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the same San Diego board covers its catalog-reagent business and its contract work, and roles can't be split reliably. We'd rather show no number than one that isn't really this company's.
Source:
greenhouse
· Checked Nov 20, 2026
Financial Intelligence
"Our TriLink business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"In addition to catalog and custom products, the business provides contract development and manufacturing (“CDMO”) services, including process development, scale-up, and GMP production for clinical and commercial applications."
"Overview
We are a life sciences company that provides products and services supporting the development and manufacture of drug therapies, diagnostics, vaccines and cell and gene therapies."
"Item 2.02 Results of Operations and Financial Condition: On August 6, 2026, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K."
"Item 1.01 Entry into a Material Definitive Agreement: On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent."
"Item 1.02 Termination of a Material Definitive Agreement: On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder."
"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet arrangement of a Registrant: The information set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference."
"Item 5.07 Submission of Matters to a Vote of Security Holders: On May 26, 2026, Maravai LifeSciences Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). On March 27, 2026, the record date for the Annual Meeting, the Company had an aggregate of 258,180,170 shares of common stock outstanding, consisting of 147,496,090 shares of Class A common stock and 110,684,080 shares of Class B common stock (together, the “Common Stock”). The holders of a total o"
"Our TriLink business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"In addition to catalog and custom products, the business provides contract development and manufacturing (“CDMO”) services, including process development, scale-up, and GMP production of nucleic acids for clinical applications."
"Overview
We are a life sciences company that provides products and services supporting the development and manufacture of drug therapies, diagnostics, vaccines and cell and gene therapies."
"Item 2.02 Results of Operations and Financial Condition: On May 7, 2026, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the first quarter of 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K."
"We develop and manufacture mRNA products to support therapeutic, including cell and gene therapies (“CGT”), and vaccine programs from preclinical development through clinical phases, including process scale-up and analytical development services."
"Our oligonucleotide products support applications including therapeutics,
in vitro
diagnostics, next-gen sequencing (“NGS”) and CRISPR-based gene editing (guide RNA)."
"Our customers manufacture a broad range of biopharmaceutical products including monoclonal antibodies and recombinant proteins, both as novel biologics and biosimilars, recombinant vaccines, and cell and gene therapies."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"(“Molecular”) expanding TriLink Biotechnologies, LLC’s (“TriLink”) ability to enable customers to develop next-generation mRNA and clustered regularly interspaced short palindromic repeats (“CRISPR”) nucleic acid-based therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and cell and gene therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics including cell and gene therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and cell and gene therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics including cell and gene therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
"(also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a leading life sciences company dedicated to providing critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics."
"The nucleic acid production market includes the production and synthesis of reagents for research and manufacturing of DNA and RNA-based biologics, including cell and gene therapies, mRNA therapeutics and synthetic biology approaches."
"Cell and gene therapy programs also leverage mRNA across multiple therapeutic modalities, such as CRISPR/Cas9, transcription activator-like effector nucleases (TALENs), enzyme replacement therapies, allogeneic CAR-T cells, and base editing."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics including cell and gene therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics including cell and gene therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
"Our Nucleic Acid Production business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”)."
"These products and services enable the detection of impurities that occur in the manufacturing of biologic drugs and other therapeutics including cell and gene therapies."
"From inventive startups to the world’s leading biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex discovery challenges and help them streamline and scale their supply chain needs beginning from research and development through clinical trials to commercialization."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Company Signals 1 articles
Company announcements, not verified evidence. They do not change any score.
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP - Business Wire
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP Business Wire
Frequently Asked Questions About TriLink BioTechnologies
What is TriLink BioTechnologies's CDMO Signal Score?
TriLink BioTechnologies has a Signal Score of 63/100, based on quality, operations, financial stability, and capacity data.
Evaluating TriLink BioTechnologies for a manufacturing program?
Use the free AI matchmaker to compare TriLink BioTechnologies against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
RiboBio
Guangzhou, China
Signal Score: 59.0
Oligonucleotide, mRNA
Compare TriLink BioTechnologies with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.